Regeneron Ventures Launches $500 Million Fund to Accelerate Life Sciences Innovation

Regeneron Ventures has launched as a new $500 mn venture capital fund aimed at investing in early to late-stage life sciences companies. This initiative, which is part of Regeneron’s strategy to support innovative biotechnology and medical technology advancements, will target companies that are developing therapeutics, with a focus including genetic medicines, cancer treatments, and infectious diseases.

The following article originally appeared in Yahoo Finance.

Regeneron Ventures announces its formation as a venture capital fund focused on promising biopharmaceutical, health care and health technology companies. The fund’s general partner will be independently managed by former Regeneron executives Jay S. Markowitz, M.D., and Michael Aberman, M.D., who together will lead investment strategy of the fund. Regeneron Pharmaceuticals, Inc. is the fund’s exclusive limited partner and has committed $100 million annually for five years.

“Understanding that the most groundbreaking, transformative approaches to preventing and treating disease may yet to be discovered, the fund will invest for the long-term, agnostic to therapeutic area, technology and stage of development,” said Markowitz.

Drs. Markowitz and Aberman both started their professional careers in medicine before transitioning into investing and operational roles in biotech. They share Regeneron’s patient-centric mission and commitment to doing well by doing good.

“Our goal is to cultivate an ecosystem where the next generation of biotech companies can thrive, drawing on the lessons learned and successes achieved at Regeneron and throughout our careers,” said Aberman. “Together, we will strive to identify and support groundbreaking advancements that push the boundaries of what's possible in science and medicine.”

For more, please find the original story source here.